Clinical Trial Update: Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cetuximab with or without brivanib in patients with K-Ras wild type metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Brivanib (brivanib)
• Cetuximab (cetuximab)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED